求助书籍

wenwen629

Dübel, Stefan (ed.)
- R- w. E' ?8 g9 ]6 D4 e. i8 BHandbook of Therapeutic Antibodies5 G1 k. x  h( @  ^/ m" A. ]& g2 S
Technologies, Emerging Developments and Approved Therapeutics/ T9 t) `& X% h. ~; Z
' }# ]9 b0 H9 }  t6 Q
1. Edition - July 20102 e; H6 q1 c& c" z# k
199.- Euro
7 \6 w% c; P' A" d2 [4 q0 K2010. XLVI, 1204 Pages, Softcover7 u( d3 J) l. C) S9 q6 W
200 Fig. (100 Colored Fig.)) c0 q% E9 Y* ~) [" T
- Handbook/Reference Book -
" _8 x+ [! k5 b# n% p* |, ^ISBN-10: 3-527-32902-1) m8 |: i: e6 B  V# O3 Q; W# q
有目录也可，求书！

hdc2001

我也想要。

hdc2001

Section I: Technologies
( N/ y3 z2 N* p* J, E0 W) dForeword
9 w( U) S! m. q- q7 N4 dA Greeting from the Editor
8 w) W  j* N( W  k; ^) Z$ gPART 0: INTRODUCTION$ h! V% e" j: ?2 A3 `
Therapeutic Antibodies - From Past to Future
: E3 E: u3 f0 EPART I: SELECTING AND SHAPING THE ANTIBODY MOLECULE
8 y! w: U+ p4 d) d" HSelection strategies I: Monoclonal Antibodies
' g$ @2 `. _; P# ~! hSelection strategies II: Antibody Phage Display, Q& B* K1 \# R/ c
Selection strategies III: Transgenic Mice
: e& j- A6 q; F$ v3 s  p) }- OBioinformatic Tools for Antibody Engineering& N9 S# R% Y% X: r- ]* V3 `, a; S- d/ P
Molecular Engineering I: Humanization4 S" |1 T, r2 y
Molecular Engineering II: Affinity Maturation # w) \$ z- k; Z1 D; R- L( A4 `
Molecular Engineering III: Fc Engineering( L* Q4 B7 A* i8 v+ e+ ^
PART II: THE WAY INTO THE CLINIC/ r- l+ A) o1 E* \
Production and Downstream Processing % o* X7 g7 C! c% b  l
Pharmaceutical Formulation and Clinical Application/ {3 y( h1 g+ [- B/ `
Immunogenicity of Antibody Therapeutics * s3 R% s6 K- S: D& i* H
Regulatory Considerations6 M$ {5 A8 z7 y3 ?4 \; l- B) }8 C
Intellectual Property Issues 6 r. m# c8 u8 o8 ^1 Y

$ G& O- z8 p) ]" T! w% J8 GSection II: Emerging Developments
) h# [% a2 a$ w* jPART III: BEYOND IGG: MODIFIED ANTIBODIES# D5 b1 \* Z" }
Immunoscintigraphy and Radioimmunotherapy
7 _0 F9 j+ D% R' n$ x: w% YBispecific Antibodies
0 ^1 r  D2 c: e* `% t' uImmunotoxins /
5 n( J: W1 ~- F# Z% ?4 j+ P* n& ~Targeted RNases 2 \+ P4 w  o  r. K/ p! R& H* u
PART IV: EMERGING CONCEPTS, _2 W! S/ l8 ], H+ ?, r
Automation of Selection and Engineering
% t  E  V( w9 E! i( o) _9 ZEmerging Technologies for Antibody Selection / x! I/ h4 U4 m
Emerging Alternative Production Systems
  j; f- E5 F' s4 w* z  xNon-Antibody Scaffolds
$ e7 o. ^7 q# x4 r7 Y" t9 ?1 nEmerging Therapeutic Concepts I: ADEPT
9 `0 o* m5 W: z! f" HEmerging Therapeutic Concepts II: Nanotechnology 3 X& F3 S+ z9 Q; K# t2 R
Emerging Therapeutic Concepts III:Cell-bound antibodies1 d9 O3 N' Z7 N, }- J! H
Emerging Therapeutic Concepts IV:Anti-idiotypic Antibodies
/ y& A# ~3 s0 W( V; H) C8 C  N' }PART V: ONGOING CLINICAL STUDIES:) w7 B" P. I0 `. i# _5 f/ L( I4 P
Antibodies in Phase I/II/III: Cancer Therapy
& Y- }. E8 w) o* i8 {5 wAntibodies in Phase I/II/III: Targeting TNF$ [/ E! {, C* \: z* E$ `+ ?- ]# l
  _# H0 y5 J7 r  W, r" ^
Section III: APPROVED THERAPEUTICS
$ g% j: d7 ]) t7 s7 Z& c, a( c5 HAdalimumab (Humira)2 S$ y- i1 d6 n* {
Alemtuzumab (Mabcampath)  y* e+ z# I0 i
Bevacizumab (Avastin)2 I! O# c% l0 v* `/ T
Cetuximab (Erbitux)
5 Z9 _. n1 s8 VEfalizumab (Raptiva)
9 ~9 S2 z4 B  h! N4 VFanolesomab/Technetium99m (Neutrospec)% t% {$ {1 U: r+ U
Gemtuzumab Ozogamicin (Mylotarg)
5 c' C" M- l) L( \& c. IInfliximab (Remicade)9 p0 z3 s" @, f3 k4 f" N' E3 E
Muromonab (Orthoclone)
( u6 }/ C( d( P9 U/ q6 H0 oNatalizumab (Tysabri)
8 v% H% D7 s2 iOmalizumab (Xolair)
( H7 T0 v% `; ^/ E6 z  J* ]' lPalivizumab (Synagis): t* I* R8 K1 l! L/ f! h) A% M
Rituximab (Rituxan)4 f' ]7 z; L5 [
Trastuzumab (Herceptin)1 b! _6 R$ |  k5 ~4 D
Overview: Abciximab, Arcitumomab, Basiliximab, Capromab, Cotara, Daclizumab, Edrecolomab, Igovomab, Nofetumomab, Satumomab, Sulesomab, Tositumomab and Votumumab; l9 J* `) C' [! V
Yttrium-90 Ibritumomab Tiuxetan (Zevalin)2 C) ~& r; `/ K3 X& c

wenwen629

回复 hdc2001 的帖子8 t# |- g! R$ J( S7 w  x0 k. {
! V: Q& l6 N) I; i
谢谢。